Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)

NAUnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DIAGNOSTIC_TEST

SPECT/CT

SPECT/CT imaging can generate 3-dimensional images of the location where the PSMA radioligand therapy has accumulated in the body. SPECT/CT imaging can also measure doses of radiation delivered to those locations.

Trial Locations (1)

49503

RECRUITING

BAMF Health, Grand Rapids

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BAMF Health

OTHER